Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
Marianne J DaviesEmily DuffieldPublished in: Clinical journal of oncology nursing (2021)
Durvalumab has established efficacy in patients with unresectable stage III NSCLC and is now the standard of care following CRT. Nurses need to be trained to recognize potential immune-related AEs in patients treated with immune checkpoint inhibitors.
Keyphrases
- healthcare
- mental health
- small cell lung cancer
- quality improvement
- palliative care
- squamous cell carcinoma
- heart failure
- resistance training
- pain management
- chronic pain
- body composition
- climate change
- atrial fibrillation
- human health
- cardiac resynchronization therapy
- brain metastases
- epidermal growth factor receptor